Eric Lefkofsky’s Tempus Nabs an Additional $200M for Expansion
Tempus, an Eric Lefkofsky’s project, garnered an extra $200 million in the new round of funding that took place in March 2019. The multi-million-dollar startup is a trailblazer in precision medicine. Analysis of clinical and molecular data is what the project thrives on. While Eric Lefkofsky has financed the initial stages of the project, fellow investors have since chipped in to expand it beyond best cancer treatment. Baillie Gifford, NEA, Franklin Tempelton, Revolution Growth, Novo Holdings, and accounts run by T.Rowe Price all contributed generously towards the startup. Tempus says it will utilize the funds to drive into new geographies and therapeutic areas, with a view of expanding operations The Chicago-based project uses Next-Gen sequencing, artificial intelligence, and machine learning to help medical researchers make data-oriented decisions. Over the years, Eric Lefkofsky has partnered with multiple institutions and experts.
That includes hospitals, cancer facilities, top renowned physicians, CancerLinQ, and academic research centers. The company says its latest round of funding brings the total figures to $520M. Lefkofsky, who doubles up as CEO, said the cash injection would aim to empower healthcare stakeholders. Not only will they get medical insights obtained from rich molecular data, but also based on real-world scientific evidence. Meanwhile, in a groundbreaking collaboration with Stanford Medical Center, Tempus collected blood samples for personalized blood cancer research. The samples were taken to its headquarters to test probable drug related treatments against the ailment. After that, Stanford medics used the data to craft a report with customized recommendations for future treatment prospects.
Be the first to reply